Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

• Published in: Emerging infectious diseases Vol. 28; no. 5; pp. 1050 - 1052
• Main Authors: Tober-Lau, Pinkus, Gruell, Henning, Vanshylla, Kanika, Koch, Willi M., Hillus, David, Schommers, Philipp, Suárez, Isabelle, Suttorp, Norbert, Sander, Leif Erik, Klein, Florian, Kurth, Florian
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.05.2022; Centers for Disease Control and Prevention
• Subjects: 2019 novel coronavirus disease; Antibodies, Neutralizing; Antibodies, Viral; coronavirus disease; COVID-19; Cross-Variant Neutralizing Antibodies after SARS-CoV-2 Breakthrough Infections; Drug dosages; Humans; Infections; Infectious diseases; mRNA vaccines; Mutation; Research Letter; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccination; viruses; Germany; Berlin Germany; viruses; vaccines; neutralizing antibody; zoonoses; mRNA; immunity; respiratory infections; COVID-19; B cell; SARS-CoV-2; severe acute respiratory syndrome coronavirus 2; 2019 novel coronavirus disease; coronavirus disease
• ISSN: 1080-6040; 1080-6059; 1080-6059
• DOI: 10.3201/eid2805.220271

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.